



Charles M. Lizza

Phone: (973) 286-6715

Fax: (973) 286-6815

clizza@saul.com

www.saul.com

March 10, 2025

VIA ECF

The Honorable Claire C. Cecchi, U.S.D.J.
United States District Court
Martin Luther King, Jr. Federal Building
50 Walnut Street
Newark, New Jersey 07101

The Honorable Leda D. Wettre, U.S.M.J.
United States District Court
Martin Luther King, Jr. Federal Building
50 Walnut Street, Room 2060
Newark, New Jersey 07101

Re: *Boehringer Ingelheim Pharm., Inc., et al. v. Anobri Pharm. US, LLC*
Civil Action No. 23-3530 (CCC)(LDW) (consolidated)

Boehringer Ingelheim Pharm., Inc., et al. v. Anobri Pharm. US, LLC
Civil Action No. 24-9135 (CCC)(LDW)

Dear Judge Cecchi and Judge Wettre:

This firm, together with Covington & Burling LLP, represents Boehringer in the above-captioned matters.

We write to inform the Court that on March 7, 2025, Boehringer informed FDA that it was requesting removal of the asserted patents from the Orange Book for the NDAs and products at issue in the above-captioned actions. As a result, the 30-month stays that resulted from the filing of these cases will be terminated.

Boehringer requested removal of the asserted patents from the Orange Book in light of the Federal Circuit's decision in *Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC*, No. 24-1936 (Fed. Cir.), and its denial of the petition for rehearing on March 3, 2025. We will be prepared to discuss this further with the Court during this morning's 11:30 a.m. telephone conference with Judge Wettre.

Thank you for Your Honors' kind attention to these matters.

Respectfully yours,

A handwritten signature in blue ink, appearing to read "Charles M. Lizza".

Charles M. Lizza

cc: All counsel of record (via email)